Authors: SIBILLE M DEIGAT N JANIN A KIRKESSELI S DURAND DV

Citation: M. Sibille et al., ADVERSE EVENTS IN PHASE-I STUDIES - A REPORT IN 1015 HEALTHY-VOLUNTEERS, European Journal of Clinical Pharmacology, 54(1), 1998, pp. 13-20

Authors: ZENONE T REVOL A DURIEU I GRANGE C SIBILLE M GONNAUD PM VITALDURAND D LEVRAT R

Citation: T. Zenone et al., CARBON-MONOXIDE POISONING, La Revue de medecine interne, 18, 1997, pp. 308-310

Authors: SIBILLE M BRESSON V JANIN A BOUTOUYRIE B REY J DURAND DV

Citation: M. Sibille et al., CRITICAL LIMITS TO DEFINE A LAB ADVERSE EVENT DURING PHASE-I STUDIES - A STUDY IN 1134 SUBJECTS, European Journal of Clinical Pharmacology, 52(2), 1997, pp. 81-86

Authors: LEROUX Y BORG ML SIBILLE M THEBAULT J RENOUX A DOUIN MJ DJEBBAR F DAIN MP

Citation: Y. Leroux et al., BIOAVAILABILITY STUDY OF MENOREST(R), A NEW ESTROGEN TRANSDERMAL DELIVERY SYSTEM, COMPARED WITH A TRANSDERMAL RESERVOIR SYSTEM, Clinical drug investigation, 10(3), 1995, pp. 172-178

Authors: SIBILLE M LASSONERY LG JANIN A DEIGAT N BOUTOUYRIE B DURAND DV

Citation: M. Sibille et al., UPPER LIMIT OF PLASMA ALANINE AMINO TRANSFERASE DURING PHASE-I STUDIES, European Journal of Clinical Pharmacology, 47(5), 1995, pp. 417-421

Authors: OLAGNIER V SIBILLE M DURAND DV DEIGAT N BALTASSAT P LEVRAT R

Citation: V. Olagnier et al., CRITICAL LIMIT OF BILIRUBIN CONCENTRATION FOR SELECTION OF HEALTHY-VOLUNTEERS TO PHASE-I STUDIES, Therapie, 48(6), 1993, pp. 617-622